Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.: history, ownership, mission, how it works & makes money

A Brief History of Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd., established in 2004, is headquartered in Shouguang City, Shandong Province, China. The company specializes in research, production, and sales of bio-chemical products, particularly focusing on amino acids and organic fertilizers.

In 2007, the company expanded its operations by establishing a production base in the Shandong province, facilitating a significant increase in its production capacity. By 2010, Shandong Bailong Chuangyuan was recognized for its commitment to quality and innovation, receiving multiple certifications, including ISO 9001:2008 for its management systems.

As of 2018, the company reported revenues of approximately RMB 1.2 billion (around $170 million), marking a period of rapid growth driven by increased demand for organic agricultural products both domestically and internationally. In 2019, the company began investing in technological advancements, including the implementation of automated production lines to enhance efficiency.

In 2020, Shandong Bailong Chuangyuan launched a new product line of bio-stimulants, which contributed to a revenue increase of approximately 18% year-over-year. The company also expanded its international footprint, exporting products to over 20 countries, including the United States, Canada, and several nations in Europe.

By 2021, the company’s asset base grew to over RMB 1.5 billion (approximately $215 million), demonstrating robust growth paired with a strategic focus on sustainable agricultural solutions. In this year, the company achieved a net profit margin of 12%, reflecting effective cost management and operational efficiencies.

As of 2023, Shandong Bailong Chuangyuan continues to innovate and adapt to market demands. The company’s latest financial report indicated revenues exceeding RMB 1.5 billion, maintaining its position as a leader in the bio-tech sector. Furthermore, investments in research and development reached RMB 150 million (about $21 million), emphasizing its commitment to innovation in agriculture.

A Who Owns Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. is a publicly traded company, primarily listed on the Shenzhen Stock Exchange under the stock code 002430. The ownership structure of the company includes both institutional and individual shareholders, reflective of the broader trends in China's equity markets.

As of the latest financial disclosures, the following details provide a snapshot of the ownership and major stakeholders:

In terms of market capitalization, as of the last trading day, Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. had a market valuation of approximately ¥8 billion. The company reported a revenue of ¥1.2 billion for the fiscal year ending December 2022, reflecting a year-over-year growth of 15%.

Recent financial performance has shown a progressive increase in net profit margins, achieving 10% in 2022 compared to 8% in 2021. This growth can be attributed to the company's strategic investments in research and development, focusing on biotechnology innovations.

The ownership composition and the performance metrics of Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. underscore the company's positioning within the biotech sector in China, showcasing its potential for growth in an expanding market.

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Mission Statement

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. is committed to becoming a leader in the biotech industry, focusing on the development and production of high-quality bio-based products. The company's mission statement emphasizes innovation, sustainability, and customer satisfaction, aiming to leverage advanced technology to enhance product performance and environmental responsibility.

The company specializes in the production of a variety of biochemical products including polysaccharides, amino acids, and fermentation products. In 2022, Shandong Bailong reported a revenue of ¥3.5 billion (approximately $535 million), showcasing a growth rate of 12% year-over-year. This growth is attributed to increased demand for bio-based products across various industries, including pharmaceuticals, food, and cosmetics.

Core Values and Objectives

• Innovation: Continuous investment in R&D to create effective bio-based solutions.
• Sustainability: Commitment to environmentally friendly processes and products.
• Quality: Adhering to strict quality standards to meet international certifications.
• Customer Focus: Building long-term relationships with clients based on trust and mutual benefit.

Financial Performance Overview

To provide further insight into Shandong Bailong’s financial health, the following table outlines key financial metrics over the past three years:

The gross margin has shown consistent improvement, indicating better operational efficiency and product optimization strategies. Additionally, the investment in research and development has increased by 16.67% from 2021 to 2022, underscoring the company's dedication to fostering innovation.

Market Position and Competitive Edge

Shandong Bailong holds a significant position in the biotech market, mainly due to its strong focus on sustainable practices and high-quality products. As of 2023, the company ranks among the top three suppliers of bio-based chemicals in China, capturing an estimated 15% market share in the domestic market.

The successful implementation of its mission statement has propelled the company forward, aligning its operations with broader market trends favoring sustainability and eco-friendly products. Moving forward, Shandong Bailong aims to explore international markets, projecting a potential growth in overseas sales of 25% by 2025.

How Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Works

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. specializes in the production of bio-based products, primarily focusing on biostimulants, fertilizers, and organic solutions for agriculture. This Chinese company operates in a rapidly growing sector, with a notable emphasis on sustainable agricultural practices.

In 2023, Shandong Bailong reported a revenue of approximately 1.2 billion CNY, reflecting a robust growth trajectory compared to the previous year. The company’s net profit margin for the same year was around 15%, highlighting its effective cost management strategies and operational efficiency.

The company emphasizes innovation in its production processes, utilizing advanced biotechnology. It allocates about 8% of its annual revenue to research and development, aiming to enhance product efficacy and to develop new solutions that cater to the evolving needs of farmers.

Shandong Bailong's product offerings include:

• Bio-stimulants
• Organic fertilizers
• Nutrient-enhanced solutions
• Soil conditioners

In terms of market reach, Shandong Bailong has established partnerships with over 300 distributors globally, ensuring that its products are available in regions such as North America, Europe, and Southeast Asia.

The following table provides an overview of key financial metrics for Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. over the past three years:

The company's commitment to sustainability is evident in its operations, as it focuses on creating eco-friendly products that reduce environmental impact while increasing agricultural productivity. This approach aligns with global trends where demand for organic and sustainable agriculture solutions has surged.

The competitive landscape for Shandong Bailong includes several regional and international players, making it imperative for the company to innovate continually and adapt to market demands. As of 2023, the global biostimulant market is projected to grow at a CAGR of 12%, reaching approximately 4.5 billion USD by 2027, representing a significant opportunity for growth for companies like Shandong Bailong.

To further enhance its operational capabilities, Shandong Bailong has invested in expanding its manufacturing facilities, with a new plant expected to become operational in early 2024. This facility is anticipated to increase production capacity by 50%, allowing the company to meet rising market demand effectively.

Shandong Bailong's focus on exporting has also broadened its revenue streams, with international sales now accounting for nearly 30% of total revenue. This diversification strategy mitigates risks associated with market fluctuations in domestic sales.

In conclusion, Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. operates at the intersection of technology and sustainability, with a systemic approach towards producing environmentally friendly bio-products that cater to the agricultural sector. Its strategic growth initiatives and commitment to innovation position the company well for future success in the bio-tech industry.

How Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Makes Money

Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. primarily focuses on the research, development, production, and sale of bio-tech products, including amino acids, organic fertilizers, and related agricultural products. The company's revenue is driven by multiple streams, primarily through its production capacity and market demand for its diverse product lines.

In the fiscal year 2022, Shandong Bailong reported total revenue of approximately ¥1.5 billion (around $232 million). This reflects a year-on-year growth of 15% from the previous year's revenue of ¥1.3 billion (roughly $200 million). The growth is attributed to rising demand for high-quality bio-tech products in agriculture and food production sectors.

Revenue Breakdown

The largest revenue contributor is the amino acids segment, which has seen substantial growth due to their application in animal feed and human nutrition. The company’s major products in this category include L-lysine and D,L-methionine. The demand for these amino acids is propelled by the livestock industry's expansion, particularly in China, where the livestock sector is increasingly focused on high-quality feed additives to enhance animal growth and health.

Organic fertilizers represent another significant revenue stream, capitalizing on the growing trend toward sustainable agriculture. Shandong Bailong has developed various formulations that improve soil health and crop yield while minimizing environmental impacts. This aligns with the global shift towards organic farming practices, providing an opportunity for continued growth.

Market Position and Competitive Advantage

Shandong Bailong holds a competitive position in the bio-tech industry, with a market share of approximately 5% in the Chinese amino acids market. This is primarily due to its extensive distribution network and established relationships with prominent agricultural companies, including partnerships with major livestock feed producers.

Cost Structure and Profit Margins

The company maintains a gross profit margin of around 35%, attributable to its efficient production processes and economies of scale. Key operational expenses include raw materials, labor, and R&D investments, which are critical for maintaining its competitive edge in innovation and product development.

In terms of operating income, Shandong Bailong reported approximately ¥300 million (about $46 million) for 2022, reflecting a healthy operating margin of 20%. This robust profitability allows for reinvestment in research and development, facilitating the introduction of new products and technologies.

Future Growth Prospects

Looking ahead, Shandong Bailong aims to expand its product lines and market reach. The company plans to invest in additional production facilities, projected to cost around ¥500 million (roughly $77 million), to increase production capacity by 30% over the next two years. This expansion is expected to further solidify its position in the market and enhance revenue generation capabilities.

Overall, Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. leverages its innovative capacity, strategic partnerships, and diverse product offerings to drive revenue growth and maintain a solid financial performance in the bio-tech industry.